AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02037711
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
Trial: NCT04523090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills with no active ingredient.
Trial: NCT01823835
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
Trial: NCT02317809
Drug: Liquid pergoveris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
Trial: NCT01114360
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Trial: NCT01114360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
Trial: NCT01919424
Drug: Methacholine Chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma
Trial: NCT00266344
Drug: Placebo / Duration of Treatment 3 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03605069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be applied topically once daily for 8 weeks of treatment.
Trial: NCT02811783
Drug: Placebo Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TID for 2 weeks
Trial: NCT03732365
Drug: Standard of Care Antibiotic Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
Trial: NCT04384523
Drug: OsrHSA 20 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
Trial: NCT04384523
Drug: OsrHSA 40 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
Trial: NCT04384523
Drug: OsrHSA 80 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
Trial: NCT04384523
Drug: OsrHSA 140 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
Trial: NCT04384523
Drug: OsrHSA 200 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
Trial: NCT00689793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
Trial: NCT03658070
Drug: XY0206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
Trial: NCT02981966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dapagliflozin
Trial: NCT00854503
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day in one oral administration
Trial: NCT00854503
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/day in one oral administration.
Trial: NCT00797992
Drug: Injection
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg bevacizumab
Trial: NCT00026377
Drug: SU5416
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion at assigned dose
Trial: NCT02391961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
Trial: NCT04621487
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days 500 mg bid
Trial: NCT04621487
Drug: according to antibiogram
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to antibiogram
Trial: NCT03400631
Drug: Aspiration 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration only at time 0
Trial: NCT03400631
Drug: Dextrose 1
RxNorm normalized name: DEXTROSE 10% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose injection at week 1
Trial: NCT03400631
Drug: Aspiration 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration only at week 1
Trial: NCT01417832
Drug: Resin infiltration / adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
Trial: NCT01417832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
Trial: NCT04405271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 1 tablet per day will be administered for a total of 12 weeks.
Trial: NCT01248871
Drug: procedure:sevoflurane-remifentanil/sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT01248871
Drug: propofol-remifentanil/sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT00049595
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00049595
Drug: BEACOPP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00049595
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00049595
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04216355
Drug: CAG Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term CAG derived regimen
Trial: NCT03331523
Drug: Taclonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
Trial: NCT03331523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
Trial: NCT00566254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02635997
Drug: antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00357383
Drug: Azithromycin (T1225)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00134381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
Trial: NCT03692416
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Trial: NCT04223609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone-matched placebo tablet
Trial: NCT02645617
Drug: Varnish
RxNorm normalized name: dental polish-varnishes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to the teeth
Trial: NCT00735371
Drug: LDX 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Trial: NCT00735371
Drug: LDX 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Trial: NCT00735371
Drug: LDX 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Trial: NCT00735371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical to test product.
Trial: NCT01875718
Drug: UC1010
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01875718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01808885
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule shells with identical appearance as the active compound TRO19622
Trial: NCT00351182
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00351182
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00718341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01188577
Drug: Epinephrine Inhalation Aerosol, HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
Trial: NCT01188577
Drug: Epinephrine Inhalation Aerosol
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
Trial: NCT04419688
Drug: STT-5058
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody STT-5058
Trial: NCT04419688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to STT-5058
Trial: NCT01245673
Drug: Revlamid® (Lenalidomide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
Trial: NCT00354172
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
Trial: NCT01640665
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
Trial: NCT02699372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05330650
Drug: Coated Vicryl+
RxNorm normalized name: VICRYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
Trial: NCT05330650
Drug: Vicryl
RxNorm normalized name: VICRYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
Trial: NCT02699372
Drug: RO6889450
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02528357
Drug: GSK3174998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
Trial: NCT01397604
Drug: GLA-AF
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
Trial: NCT01142024
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
Trial: NCT03691779
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet orally once daily in the morning.
Trial: NCT00267150
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT01864161
Drug: gluconate iron
RxNorm normalized name: IRON (AS FERROUS GLUCONATE)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
Trial: NCT01864161
Drug: Liposomal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sideral forte 30 mg/die
Trial: NCT02068560
Drug: dDAVP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04482569
Drug: XNW4107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
Trial: NCT00957437
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose, ER formulation 1
Trial: NCT00957437
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER formulation 1, bid for 5 days
Trial: NCT00957437
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose, ER formulation 2
Trial: NCT00806468
Drug: Desmotabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
Trial: NCT00167934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given at same frequency as Valproate
Trial: NCT02983422
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
Trial: NCT06312033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
Trial: NCT02051023
Drug: FML 0.1% eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
Trial: NCT02051023
Drug: Liquifilm artificial tears eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquifilm instillation 4 times a day for 22 days
Trial: NCT00496132
Drug: PRO131921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses by IV infusion
Trial: NCT01228292
Drug: Citrasate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrasate is infused as a dialysate
Trial: NCT01760811
Drug: Erbitux,merck serono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
Trial: NCT03327168
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
Trial: NCT01027260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dosing
Trial: NCT00710242
Drug: DF01
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Trial: NCT00710242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Trial: NCT03006302
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
Trial: NCT00782613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a cream formulation
Trial: NCT01925300
Drug: Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab
RxNorm normalized name: rosuvastatin calcium 20 MG [Crestor]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00861211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00048750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00167661
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
Trial: NCT03536039
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose of 50 mg/mq
Trial: NCT03536039
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose of 750 mg/mq
Trial: NCT00918554
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Trial: NCT00918554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.